Frontiers in Pharmacology (Jun 2024)

Case report: a cataract induced by bleomycin in a patient with testicular cancer

  • Wan Zhang,
  • Wan Zhang,
  • Yinghua Ji,
  • Yinghua Ji,
  • Yufei Sun,
  • Yufei Sun,
  • Keya Zhi,
  • Keya Zhi,
  • Han Yang,
  • Han Yang,
  • Min Zhang,
  • Min Zhang,
  • Ping Lu,
  • Ping Lu,
  • Yana Zhang,
  • Yana Zhang

DOI
https://doi.org/10.3389/fphar.2024.1339662
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundBleomycin is a glycopeptide antibiotic with outstanding anti-tumor effects. A major adverse effect of bleomycin is lung fibrosis. However, the development of cataracts as a severe adverse effect has not been reported.Case summaryHerein, we describe the first case of cataract induced by bleomycin therapy in a 22-year-old male with testicular cancer. After surgical intervention and following five successive chemotherapy cycles of the BEP regimen, including bleomycin, etoposide and cisplatin, the patient reported a gradual painless loss of vision, with substantial decline in visual ability, especially in the right eye. Following comprehensive eye examinations, a cataract was diagnosed. Eventually, the patient underwent phacoemulsification and received replacement of the intraocular lenses.ConclusionBleomycin can cause cataracts, which induces a significant loss of vision. Therefore, clinicians should observe early symptoms and properly adjust treatment to prevent aggravation of symptoms.

Keywords